REGENXBIO Inc.RGNXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 70% recommend buying.

Consensus Rating

Buy

20 analysts·High coverage

70%

Rating Distribution

Strong Buy

15%

Buy

1365%

Hold

525%

Sell

15%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 215% higher.

Bear Case

$20.00

+86%

Consensus

$34.00

+215%

Bull Case

$45.00

+317%

Price Range20 analysts

Low

Consensus

High

$20.00

$45.00

Current Target

Current Price

$10.78

Upside to Target

$23.22

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.93(8 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+35.34%

EPS—

FY2028

Rev+57.11%

EPS—

FY2029

Rev+34.74%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-7.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 29, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Target:$34.00

+195.1%from $11.52

Jan 27, 2026Barclays

Regenxbio assumed with an Overweight at Barclays

Target:$37.00

+175.9%from $13.41

Dec 19, 2025Stifel Nicolaus

Regenxbio price target raised to $45 from $40 at Stifel

Target:$45.00

+233.1%from $13.51

Dec 15, 2025Leerink Partners

Regenxbio Inc. (RGNX) PT Raised to $20 at Leerink Partners

Target:$20.00

+44.1%from $13.88

Mar 18, 2025Leerink Partners

Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink

Target:$24.00

+207.7%from $7.80

Jan 7, 2025RBC Capital

Regenxbio price target lowered to $30 from $35 at RBC Capital

Target:$30.00

+258.9%from $8.36

Nov 15, 2024Morgan Stanley

Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight

Target:$22.00

+97.5%from $11.14

Oct 10, 2024Raymond James

Regenxbio reinstated with an Outperform at Raymond James

Target:$18.00

+96.0%from $9.19

Sep 5, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Target:$39.00

+242.9%from $11.38

Jun 24, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)

Target:$40.00

+212.7%from $12.79

Jun 7, 2024Goldman Sachs

Goldman Sachs Starts Regenxbio Inc. (RGNX) at Buy

Target:$38.00

+176.2%from $13.76

May 15, 2024H.C. Wainwright

Regenxbio price target raised to $38 from $36 at H.C. Wainwright

Target:$38.00

+140.5%from $15.80

Mar 11, 2024H.C. Wainwright

H.C. Wainwright Starts Regenxbio Inc. (RGNX) at Buy; 'Advancing Gene Therapies in Ophthalmology and Rare Diseases'

Target:$36.00

+57.5%from $22.85

Mar 8, 2024RBC Capital

RBC Capital Upgrades Regenxbio Inc. (RGNX) to Outperform

Target:$35.00

+53.8%from $22.75

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance